European Urology Focus

Slides:



Advertisements
Similar presentations
Systemic treatment of renal cell cancer: A comprehensive review
Advertisements

Volume 68, Issue 6, Pages (December 2015)
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front- line therapy with novel agents combinations  Aurelio Lopez, Maria-Victoria.
European Urology Focus
Volume 67, Issue 1, Pages (January 2015)
Volume 63, Issue 3, Pages (March 2013)
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin  Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group  Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.
GEIS guidelines for gastrointestinal sarcomas (GIST)
Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis  Maria I. Carlo, Darren R.
Volume 58, Issue 4, Pages (October 2010)
Volume 63, Issue 2, Pages (February 2013)
European Urology Focus
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer  Miguel.
European Urology Focus
Volume 62, Issue 4, Pages (October 2012)
European Urology Focus
Volume 70, Issue 6, Pages (December 2016)
Determination of vhl Gene Mutations in Sporadic Renal Cell Carcinoma
Renal Cell Carcinoma: Prognostic Factors and Patient Selection
Volume 49, Issue 2, Pages (February 2006)
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group  Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.
Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Volume 69, Issue 1, Pages (January 2016)
European Urology Oncology
Volume 67, Issue 1, Pages (January 2015)
Volume 51, Issue 5, Pages (May 2007)
Volume 70, Issue 5, Pages (November 2016)
Volume 73, Issue 4, Pages e116-e118 (April 2018)
Volume 63, Issue 1, Pages (January 2013)
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Volume 66, Issue 2, Pages (August 2014)
Volume 65, Issue 3, Pages (March 2014)
Volume 71, Issue 1, Pages 1-3 (January 2017)
Volume 70, Issue 4, Pages (October 2016)
Volume 70, Issue 5, Pages (November 2016)
Volume 66, Issue 5, Pages (November 2014)
Volume 70, Issue 5, Pages (November 2016)
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma  Viktor Grünwald, Xun Lin, Daniel Kalanovic,
Volume 65, Issue 6, Pages (June 2014)
Volume 61, Issue 6, Pages (June 2012)
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
Volume 74, Issue 3, Pages (September 2018)
Volume 70, Issue 2, Pages (August 2016)
Volume 68, Issue 4, Pages (October 2015)
Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
Volume 62, Issue 3, Pages (September 2012)
Volume 73, Issue 4, Pages e116-e118 (April 2018)
Inflammatory response and cytokine levels induced by intralesional photodynamic therapy and 630-nm laser in a case series of basal cell carcinoma  María.
Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain  J.-M. Aguado, C. Lumbreras, D.
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Volume 63, Issue 2, Pages (February 2013)
Volume 70, Issue 6, Pages (December 2016)
Bernard Escudier  European Urology Supplements 
Long-Term Hormonal Therapy: Who Would Benefit?
Volume 75, Issue 3, Pages (March 2019)
A Mitral Heart Valve Prosthesis Hidden Under Perivalvular Pannus
Volume 75, Issue 3, Pages (March 2019)
Volume 68, Issue 5, Pages (November 2015)
Multiplexed Methylation Profiles of Tumor Suppressor Genes in Bladder Cancer  Maria José Cabello, Laura Grau, Noreli Franco, Esteban Orenes, Miguel Alvarez,
Volume 51, Issue 5, Pages (May 2007)
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Joaquim Bellmunt  European Urology Supplements 
Silvia Bielsa, MD, José Martín-Juan, MD, José M
European Urology Oncology
Volume 76, Issue 1, Pages (July 2019)
Time to Recurrence (Hormone Receptor-positive Patients)
European Urology Oncology
European Urology Oncology
Presentation transcript:

European Urology Focus A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)  Jesús García-Donas, Luis Angel Leon, Emilio. Esteban, Maria Jose Vidal-Mendez, Jose Angel Arranz, Xavier Garcia del Muro, Laura Basterretxea, Aranzazu González del Alba, Miguel Angel Climent, Juan Antonio Virizuela, Carlos Álvarez, Juan Sepúlveda, Urbano Anido, Carlos López, Maria Jose Ortiz-Morales, Xavier. Pérez, Cristina Rodriguez-Antona, Juan Francisco Rodriguez-Moreno, Susana Hernando, Daniel Castellano  European Urology Focus  DOI: 10.1016/j.euf.2016.09.004 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Progression-free survival (PFS) assessment. (A) PFS for the study population, (B) baseline circulating endothelial cell (CEC) levels and PFS, and (C) PFS for the study population separated by baseline CEC levels. CI=confidence interval; HR=hazard ratio. European Urology Focus DOI: (10.1016/j.euf.2016.09.004) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 Graphical representation of hazard ratios of prognostic variables. CI=confidence interval; MSKCC=Memorial Sloan Kettering Cancer Center. European Urology Focus DOI: (10.1016/j.euf.2016.09.004) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 3 Circulating endothelial cell (CEC) levels at baseline compared with CEC levels at tumor progression in patients who experienced disease progression during the study. European Urology Focus DOI: (10.1016/j.euf.2016.09.004) Copyright © 2016 European Association of Urology Terms and Conditions

European Urology Focus DOI: (10.1016/j.euf.2016.09.004) Copyright © 2016 European Association of Urology Terms and Conditions

European Urology Focus DOI: (10.1016/j.euf.2016.09.004) Copyright © 2016 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.